Matinas BioPharma Stock Jumps After Meningitis Candidate Data

• Matinas BioPharma Holdings Inc (NYSE: MTNB) has announced positive data from the first two cohorts of the Phase 2 EnACT trial of MAT2203 (oral amphotericin B) for cryptococcal meningitis.

• The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID).

• In the second cohort, step-down therapy with MAT2203 achieved an effective clearance of fungal organisms was 0.38, significantly higher than the prespecified primary endpoint threshold of over 0.20. Cohort 2 evaluated stepdown to MAT2203 after two days of IV amphotericin.

• There was no evidence of breakthrough or relapsed cryptococcal infections through 10 weeks. In Cohort 2, overall survival was 95% in 40 patients randomized to receiving MAT2203.

• All 39 patients completing induction with MAT2203 achieved sterility, with no evidence of breakthrough or recurrent infections during the first ten weeks of antifungal treatment.

• Enrollment in Cohort 3 of EnACT has commenced and is expected to complete by the end of 2021. Cohort 3 is the safety lead-in for Cohort 4, an all-oral MAT2203 treatment regimen.

• Price Action: MTNB shares are up 8.96% at $0.90 during the premarket session on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Valneva Shares Plunge As UK Terminates COVID-19 Vaccine Contract: What You Need Know

• HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.